A study to assess the effect of intensive uric acid (UA) lowering therapy with RDEA3170, febuxostat, dapagliflozin on urinary excretion of UA

Trial Identifier: D5495C00001
Sponsor: AstraZeneca
Contract Research Organization: USA
PAREXEL Early Phase Clinical Unit Baltimore
PAREXEL Early Phase Clinical Unit-Los Angeles
Clinical Laboratory: USA
Harbor Hospital Laboratory
GenX Laboratories Inc.
Analytical Laboratory (Pharmacokinetic Sample Analysis): USA
Covance Bioanalytical Services, LLC
NCTID:: NCT03316131
Start Date: October 2017
Primary Completion Date: July 2018

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, CA Glendale, CA, United States of America, 91206
United States of America, MD Baltimore, MD, United States of America, 21225